OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Market Closed - Boerse Frankfurt Warrants 03:46:07 2024-07-05 pm EDT | ||
| 12.15 EUR | -1.38% |
|
| Current month | +0.16% | ||
| 1 month | +35.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 12.16 | -1.30% |
| 24-07-04 | 12.32 | +1.32% |
| 24-07-03 | 12.16 | -2.72% |
| 24-07-02 | 12.5 | +0.89% |
| 24-07-01 | 12.39 | +2.06% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 03:46 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW8840 |
| ISIN | DE000SW88404 |
| Date issued | 2024-04-19 |
| Strike | 2,658 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.86 € |
|---|---|
| Lowest since issue | 7.88 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,755
DKK
Average target price
2,464
DKK
Spread / Average Target
+40.40%
- Stock Market
- Certificates
- Certificat
